DIR Return Create A Forum - Home
       ---------------------------------------------------------
       Road2HardCoreIron
  HTML https://road2hardcoreiron.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: Steriod Pictures
       *****************************************************
       #Post#: 3158--------------------------------------------------
       Human Bio Semaglutide 5 mg
       By: Road2HardCoreIron Date: April 2, 2023, 7:22 am
       ---------------------------------------------------------
       Quick Takes
       The prevalence of obesity and its associated cardiometabolic
       complications have increased to historic levels in the US, with
       a disproportionate burden among individuals in minority
       racial/ethnic groups and those with low socioeconomic status.
       However, effective therapeutic options for obesity management
       are limited.
       In this study, once weekly 2.4 mg semaglutide injection versus
       placebo in conjunction with lifestyle modification therapy among
       non-diabetic individuals with obesity (or BMI ≥27 kg/m2
       with comorbidities) caused significant improvements in body
       weight (15% reduction vs. 2.4% in the placebo arm, over 68
       weeks), cardiometabolic risk factors, self-reported physical
       functioning, and body composition, with low rates of major
       adverse effects or safety concerns.
       Obesity pharmacotherapies, including GLP-1 receptor agonists,
       are expensive and often not covered by insurance in the US,
       raising concerns for disparities in access to these medications,
       especially in populations disproportionately affected by
       obesity. There is need for improved coverage of these
       increasingly effective obesity pharmacotherapies, to enhance our
       ability to manage excess weight in clinical environments.
       *****************************************************